Loading clinical trials...
Loading clinical trials...
Three SGLT2i were commercially available in Italy at the time the trial was designed: canagliflozin, dapagliflozin, and empagliflozin. Preliminary evidence suggests that the higher dose canagliflozin ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Center for Outcomes Research and Clinical Epidemiology, Italy
Collaborators
NCT07590193 · Diabetes Mellitus, Type 2
NCT06574035 · Diabetes Mellitus, Type 2, Depressive Symptoms, and more
NCT02861781 · Obesity, Insulin Resistance, and more
NCT05692388 · Diabetic Nephropathy Type 2 - Uncontrolled, Diabetes Mellitus, Type 2, and more
NCT06513026 · Lactose Intolerance, Lactose Intolerant, and more
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions